title: Persistent bone marrow depression following short-term treatment with temozolomide.
abstract: Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme. Although generally well tolerated, haematological side effects are observed in approximately 1-10% of patients receiving TMZ. We report a case of a patient who developed severe bone marrow failure (BMF) after only 3 weeks of concomitant TMZ. The BMF was grave with no signs of improvement for 12 months, resulting in more than 100 transfusions of blood cells.
authors.affiliation: Oslo University Hospital, Oslo, Norway.
authors.forename: Kathrine
authors.initials: K
authors.lastname: Vandraas
authors.affiliation: Department of Hematology, Oslo University Hospital, Oslo, Norway.
authors.forename: Geir Erland
authors.initials: GE
authors.lastname: Tjønnfjord
authors.affiliation: Oslo University Hospital, Oslo, Norway.
authors.forename: Tom Børge
authors.initials: TB
authors.lastname: Johannesen
authors.affiliation: Oslo University Hospital, Oslo, Norway.
authors.forename: Petter
authors.initials: P
authors.lastname: Brandal
mesh_terms: D000368:Aged; D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000188:drug therapy; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000188:drug therapy; D000080983:Bone Marrow Failure Disorders; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D000069585:Filgrastim / Q000008:administration & dosage / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000601:surgery; D006457:Hemoglobinuria, Paroxysmal / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008297:Male; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D000077204:Temozolomide; D013926:Thrombopoietin / Q000008:administration & dosage / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D003606:Dacarbazine; D013926:Thrombopoietin; C488777:romiplostim; D000069585:Filgrastim; D000077204:Temozolomide